EMA’s human medicines committee (CHMP) has recommended extending the therapeutic indication of Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a rare, chronic, autoimmune …

… pressure Diabetes Chronic infections Autoimmune diseases When the kidneys get … can suggest adjustments and treatments that will slow its … fluids Steering clear of medications that put a strain … prescribe drugs to manage the inflammation or treat the underlying …

… name medications”, and to reshore domestic pharmaceutical manufacturing … autism spectrum disorders, autoimmune disease, allergies and asthma— … stated that alternative treatments such as stem … between drug developers and the FDA. While big pharma companies …

… can provide a longer treatment-free interval, significantly … in the discovery, development, manufacturing, and commercialization … into autoimmune diseases. IASO Bio boasts a robust drug development platform, … USA for several autoimmune diseases, with plans to …

… T1D pathogenesis as an autoimmune disease where destruction of … conducted 12 months after treatment, assessed by a statistical … according to the adaptive trial design. The difference between … in contrast to current drug development strategies that, driven by …

… development will mark the company’s first dedicated, fully integrated active pharmaceutical … ingredient (API) and drug product facility for … ingredients for the treatment of cancer and autoimmune diseases.  Completion of …

… when the story is developing. Whether it… two-year Australian trial found the drug Baricitinib - … this drug, which is already used to treat several autoimmune diseases, including … insulin production. When baricitinib treatment was stopped, participants …

… the AI-native pharmaceutical company revolutionizing drug development, today announced the … for decisions around which drugs to license and acquire … scalable systems that meet FDA and GxP standards. He … a new asset targeting autoimmune diseases and a recently …

Roivant Sciences Ltd ROIV and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM). Dermatomyositis is a chronic autoimmune disorder causing muscle inflammation and a distinctive skin rash, …

… first active pharmaceutical ingredient and drug product plant … treatments are primarily used to treat cancer but are being explored for autoimmune diseases … In June, the pharmaceutical giant announced plans … clinical-stage company developing genetic medicines …